Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:40 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Prevention of Delirium in Inpatients Utilizing Melatonin
NCT02654314 · Yale University · PHASE3 · terminated · last registry update 2022-03-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Lack of resources to complete the study. Descriptive statistics for the outcome measures collected are provided.” | – | Registry record, Yale University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MTNR1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-12-29Also stopped (terminated): University of Sao Paulo, Ramelteon (RozeremR) (NCT05414864)
- 2022-12-22Also stopped (terminated): University of Michigan, a drug against MTNR1A (NCT02940769)
- 2022-12-15Phase 3 first posted: Monash University, Melatonin 10 MG (NCT05651347)
- 2022-11-25Results posted on the registry: University of Michigan, Melatonin 0.5 MG (NCT03715465)
- 2022-10-06Phase 3 first posted: Ain Shams University, a drug against MTNR1A (NCT05570526)
- 2022-09-15Phase 3 first posted: Arash Afshari, Melatonin + Isotonic sodium chloride solution (NCT05541276)
- 2022-09-13Phase 3 first posted: Universitat Internacional de Catalunya, Melatonin 10 MG Oral Tablet + Hydroxycobalamin (NCT05536596)
- 2022-08-16Phase 3 first posted: Gustav Stalhammar, Melatonin (NCT05502900)
- 2022-07-26Phase 3 first posted: M.D. Anderson Cancer Center, Melatonin + Melatonin (NCT05474846)
- 2022-07-22Also stopped (withdrawn): State University of New York at Buffalo, Melatonin + Placebo (NCT04784754)
- 2022-07-14Also stopped (withdrawn): Institution de Lavigny, melatonin + placebo (NCT01370486)
- 2022-06-30Phase 3 first posted: National Taiwan University Hospital, Melatonin + Placebo (NCT05439876)
- 2022-06-13Also stopped (terminated): Centre Jean Perrin, melatonin + placebo (NCT02454855)
- 2022-06-03Also stopped (suspended): The University of Hong Kong, Melatonin + Dexamethasone Sodium Sulphate 4mg/1mL (NCT03995004)
- 2022-05-05Phase 3 first posted: Vanda Pharmaceuticals, Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension (NCT05361707)
- 2022-03-04Phase 3 first posted: Neurim Pharmaceuticals Ltd., Piromelatine 20 mg + Placebo (NCT05267535)
- 2021-11-15Also stopped (withdrawn): University of Alberta, Placebo (NCT02333149)
- 2021-11-03Results posted on the registry: Vanda Pharmaceuticals, Tasimelteon + Placebo (NCT03291041)
- 2021-10-19Phase 3 first posted: Rutgers, The State University of New Jersey, Melatonin (NCT05084196)
- 2021-10-07Also stopped (withdrawn): University of British Columbia, Melatonin (NCT02282241)
- 2021-09-09Results posted on the registry: Amy Gelfand, Melatonin (NCT02344316)
- 2021-09-02Results posted on the registry: Herlev Hospital, Melatonin + Placebo (NCT02386319)
- 2021-08-27Also stopped (terminated): Hospital de Clinicas de Porto Alegre, Melatonin Pill + Placebo oral capsule (NCT03725267)
- 2021-08-20Also stopped (terminated): Englewood Hospital and Medical Center, a drug against MTNR1A (NCT03241004)
- 2021-08-12Also stopped (withdrawn): Johns Hopkins University, Melatonin + Placebo (for Melatonin) (NCT02099331)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision